Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Any CEA-Based Price Adjustment Must Be Limited to Premium Rates: 3 Pharma Groups
October 11, 2017
- MHLW to Issue Basic Guide to PMS for Conditional Early Approval: Drug Review Chief
October 11, 2017
- Japan Needs “Quick and Low-Cost” R&D Setup: Top MD Bureaucrat
October 10, 2017
- MHLW’s JETRO NY Post Ended Because There Was No Request: Govt
October 10, 2017
- Health Minister Questions How to Gauge Success in Outcome-Based CAR-T Pricing in Japan
October 10, 2017
- Revised Ministerial Ordinance on Preventing Distribution of Counterfeit Drugs to Take Effect Jan. 31
October 10, 2017
- 3rd Round of Sakigake Invitations Begin
October 6, 2017
- Social Security Council Members Reiterate Opposition to Reference Pricing for LLPs, or LLP-Gx Uniform Prices
October 6, 2017
- MHLW to Place Priority on “Mutual Understanding” with Industry: Economic Affairs Chief
October 6, 2017
- “Pediatric Treatment”, “Innovation” Excluded from Ethical/Social Factors in Pilot CEA Program: Chuikyo
October 5, 2017
- MHLW Drops 5-Scale CEA Rating, Pitches Slope-Like Price Adjustment Model: Chuikyo
October 5, 2017
- Chuikyo Mulls over Scope of CEA-Based Price Adjustments - Premium Portion or Total NHI Price?
October 5, 2017
- Payers Oppose Price Hikes based on CEA at 1st Joint Meeting: Chuikyo
October 5, 2017
- Chuikyo Members Object to Extension of Prescription Limit for Injectable Ethical Narcotic
October 5, 2017
- MHLW Wants to Introduce Conditional Early Approval System This Month: Minister
October 3, 2017
- MHLW Presents Four Patterns for Review of Clinical Research That Falls Under “Specified Clinical Research” Category
October 2, 2017
- Drug Makers to Be Required to Disclose Donations, Lecture Fees, and Writing Fees Tied to “Specified Clinical Research”
October 2, 2017
- MHLW to Compile Guidelines for Proper Drug Promotion Activities
October 2, 2017
- (Update) Bayer Told to Improve Practice over ADR Reporting Delays, Gets “Verbal Guidance” for Xarelto Survey Fuss
October 2, 2017
- MHLW Unveils Planned Framework for Conditional Early Approval Scheme
September 29, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…